Literature DB >> 28613124

Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence.

Stefano Tamburin1, Marco Faccini2, Rebecca Casari2, Angela Federico1, Laura Morbioli2, Enrica Franchini1, Luigi Giuseppe Bongiovanni1, Fabio Lugoboni1.   

Abstract

High-dose benzodiazepine (BZD) dependence represents an emerging and under-reported addiction phenomenon and is associated with reduced quality of life. To date there are no guidelines for the treatment of high-dose BZD withdrawal. Low-dose slow flumazenil infusion was reported to be effective for high-dose BZD detoxification, but there is concern about the risk of convulsions during this treatment. We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis. In our sample, 22 patients (4.9%) reported history of convulsions when previously attempting BZD withdrawal. Only four patients (0.9%) had seizures during ( n = 2) or immediately after ( n = 2) flumazenil infusion. The two patients with seizures during flumazenil infusion were poly-drug misusers. The most common antiepileptic drugs (AEDs) used for anticonvulsant prophylaxis were either valproate 1000 mg or levetiracetam 1000 mg. Our data indicate that, when routinely associated with AEDs prophylaxis, low-dose slow subcutaneous flumazenil infusion represents a safe procedure, with low risk of seizure occurrence.

Entities:  

Keywords:  Benzodiazepine (BZD); detoxification; epilepsy; flumazenil; substance use disorders (SUD); treatment

Mesh:

Substances:

Year:  2017        PMID: 28613124     DOI: 10.1177/0269881117714050

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

Review 1.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

2.  Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers.

Authors:  Angela Federico; Fabio Lugoboni; Elisa Mantovani; Alice Martini; Laura Morbioli; Rebecca Casari; Marco Faccini; Stefano Tamburin
Journal:  Front Neurosci       Date:  2020-07-21       Impact factor: 4.677

3.  High-Dose Dependence and Cognitive Side Effects to Medical Prescription of Etizolam.

Authors:  Stefano Tamburin; Elisa Mantovani; Anna Bertoldi; Angela Federico; Rebecca Casari; Fabio Lugoboni
Journal:  Front Psychiatry       Date:  2020-11-04       Impact factor: 4.157

4.  Polysubstance Use Patterns Among High Dose Benzodiazepine Users: A Latent Class Analysis and Differences Between Male and Female Use.

Authors:  Lorenzo Zamboni; Igor Portoghese; Alessio Congiu; Thomas Zandonai; Rebecca Casari; Francesca Fusina; Anna Bertoldi; Fabio Lugoboni
Journal:  Front Psychiatry       Date:  2022-01-25       Impact factor: 4.157

5.  Addiction of High Dose of Benzodiazepine: Verona Detox Approach With Flumazenil.

Authors:  Rebecca Casari; Antonio Metastasio; Lorenzo Zamboni; Martino Biasioli; Simone Campagnari; Fabio Lugoboni
Journal:  Front Psychiatry       Date:  2022-03-31       Impact factor: 4.157

6.  Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?

Authors:  Alexander Gallo; Tim MacDonald; Kellie Bennett; Gioiamia Basso-Hulse; Gary Hulse
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

7.  Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug.

Authors:  Fabio Lugoboni; Stefano Tamburin; Angela Federico; Elisa Mantovani; Rebecca Casari; Anna Bertoldi
Journal:  J Neural Transm (Vienna)       Date:  2020-12-17       Impact factor: 3.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.